CONTEXT: Arginine vasopressin (AVP) is known to affect liver glycogenolysis, insulin, and glucagon secretion and pituitary ACTH release. We previously showed that high copeptin, the stable C-terminal fragment of AVP prohormone, is independently associated with hyperinsulinemia and future development of diabetes mellitus. OBJECTIVE: The objective of the study was to examine whether plasma copeptin is associated with components of the metabolic syndrome (MetS) independently of insulin, diabetes mellitus, and environmental factors. DESIGN, SETTING, AND PARTICIPANTS: This was a cross-sectional, population-based sample of 4742 subjects, aged 46-68 yr, 60% women, in Malmö, Sweden. MAIN OUTCOME MEASURE: Using multivariable logistic and linear regression, plasma copeptin was associated with components of the MetS. RESULTS: Copeptin quartile (lowest quartile as reference) was, after adjustment for age, sex, insulin, and diabetes mellitus, associated with hypertension (odds ratios 1.04, 1.07, 1.31; P = 0.004), abdominal obesity (odds ratios 1.21, 1.16, 1.57; P = 0.002), obesity (odds ratios 1.25, 1.15, 1.49; P = 0.01), top quartile of c-reactive protein (odds ratios 1.11, 1.13, 1.32; P = 0.007), and MetS (adjusted for age and sex only) (odds ratios 1.53, 1.77, 1.86; P < 0.001). High copeptin levels were significantly associated with high fat intake, low physical activity, and borderline significantly associated with low socioeconomic status. The association between copeptin and components of the MetS was not affected after adjustment for these environmental factors. CONCLUSIONS: Our data suggest that increased activity of the AVP system is a unifying factor in the MetS and point to a new pharmacologically modifiable system of potential importance in the treatment of MetS and prevention of cardiovascular disease.
CONTEXT: Arginine vasopressin (AVP) is known to affect liver glycogenolysis, insulin, and glucagon secretion and pituitary ACTH release. We previously showed that high copeptin, the stable C-terminal fragment of AVP prohormone, is independently associated with hyperinsulinemia and future development of diabetes mellitus. OBJECTIVE: The objective of the study was to examine whether plasma copeptin is associated with components of the metabolic syndrome (MetS) independently of insulin, diabetes mellitus, and environmental factors. DESIGN, SETTING, AND PARTICIPANTS: This was a cross-sectional, population-based sample of 4742 subjects, aged 46-68 yr, 60% women, in Malmö, Sweden. MAIN OUTCOME MEASURE: Using multivariable logistic and linear regression, plasma copeptin was associated with components of the MetS. RESULTS:Copeptin quartile (lowest quartile as reference) was, after adjustment for age, sex, insulin, and diabetes mellitus, associated with hypertension (odds ratios 1.04, 1.07, 1.31; P = 0.004), abdominal obesity (odds ratios 1.21, 1.16, 1.57; P = 0.002), obesity (odds ratios 1.25, 1.15, 1.49; P = 0.01), top quartile of c-reactive protein (odds ratios 1.11, 1.13, 1.32; P = 0.007), and MetS (adjusted for age and sex only) (odds ratios 1.53, 1.77, 1.86; P < 0.001). High copeptin levels were significantly associated with high fat intake, low physical activity, and borderline significantly associated with low socioeconomic status. The association between copeptin and components of the MetS was not affected after adjustment for these environmental factors. CONCLUSIONS: Our data suggest that increased activity of the AVP system is a unifying factor in the MetS and point to a new pharmacologically modifiable system of potential importance in the treatment of MetS and prevention of cardiovascular disease.
Authors: Ray El Boustany; Irina Tasevska; Esther Meijer; Lyanne M Kieneker; Sofia Enhörning; Guillaume Lefèvre; Kamel Mohammedi; Michel Marre; Frédéric Fumeron; Beverley Balkau; Nadine Bouby; Lise Bankir; Stephan Jl Bakker; Ronan Roussel; Olle Melander; Ron T Gansevoort; Gilberto Velho Journal: JCI Insight Date: 2018-07-12
Authors: Richard J Johnson; Peter Stenvinkel; Thomas Jensen; Miguel A Lanaspa; Carlos Roncal; Zhilin Song; Lise Bankir; Laura G Sánchez-Lozada Journal: J Am Soc Nephrol Date: 2016-06-09 Impact factor: 10.121
Authors: Harriet A Carroll; Iain Templeman; Yung-Chih Chen; Robert M Edinburgh; Elaine K Burch; Jake T Jewitt; Georgie Povey; Timothy D Robinson; William L Dooley; Robert Jones; Kostas Tsintzas; Widet Gallo; Olle Melander; Dylan Thompson; Lewis J James; Laura Johnson; James A Betts Journal: J Appl Physiol (1985) Date: 2018-11-29
Authors: S Canivell; M Mohaupt; D Ackermann; M Pruijm; I Guessous; G Ehret; G Escher; A Pechère-Bertschi; B Vogt; O Devuyst; M Burnier; P-Y Martin; B Ponte; M Bochud Journal: J Endocrinol Invest Date: 2017-12-12 Impact factor: 4.256
Authors: Estifanos N Habtemichael; Abel Alcázar-Román; Bradley R Rubin; Laura R Grossi; Jonathan P Belman; Omar Julca; Michael G Löffler; Hongjie Li; Nai-Wen Chi; Varman T Samuel; Jonathan S Bogan Journal: J Biol Chem Date: 2015-05-05 Impact factor: 5.157
Authors: A Abbasi; E Corpeleijn; E Meijer; D Postmus; R T Gansevoort; R O B Gans; J Struck; H L Hillege; R P Stolk; G Navis; S J L Bakker Journal: Diabetologia Date: 2012-04-15 Impact factor: 10.122